1. Zisova LG, Chokoeva AA, Amaliev GI, Petleshkova PV, Miteva-Katrandzhieva Tcapital Em C, Krasteva MB, Uchikova EH, Kouzmanov AH, Ivanova ZV: Vulvovaginal Candidiasis in Pregnant Women and its Importance for Candida Colonization of Newborns. Folia Med (Plovdiv) 2016, 58(2):108-114.
2. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL: Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstetrics and gynecology 2004, 104(5 Pt 1):926-930.
3. Parveen N, Munir AA, Din I, Majeed R: Frequency of vaginal candidiasis in pregnant women attending routine antenatal clinic. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2008, 18(3):154-157.
4. Nikolov A, Shopova E, Museva A, Dimitrov A: [Vaginal candida infection in the third trimester of pregnancy]. Akusherstvo i ginekologiia 2006, 45(6):7-9.
5. de Leon EM, Jacober SJ, Sobel JD, Foxman B: Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC infectious diseases 2002, 2:1.
6. Bitew A, Abebaw Y: Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health 2018, 18(1):94.
7. Consolaro ME, Albertoni TA, Svidzinski AE, Peralta RM, Svidzinski TI: Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia 2005, 159(4):501-507.
8. Tang Y, Yu F, Huang L, Hu Z: The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. Journal of Clinical Laboratory Analysis 2019, 33(1):e22644.
9. Ge SH, Wan Z, Li J, Xu J, Li RY, Bai FY: Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China. Antimicrob Agents Chemother 2010, 54(8):3126-3131.
10. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD: Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Frontiers in microbiology 2017, 7:2173-2173.
11. Chokoeva A, Kouzmanov A, Ivanova Z, Zisova L, Amalie G, Petleshkova P, Miteva-Katrandzhieva T, Krasteva M, Uchikova E: [Investigation on Antifungal Susceptibility of Candida Yeasts in Pregnant Patients with Confirmed Vulvovaginal Candidiasis and Their Newborns.]. Akush Ginekol (Sofiia) 2016, 55(4):20-29.
12. Amouri I, Sellami H, Borji N, Abbes S, Sellami A, Cheikhrouhou F, Maazoun L, Khaled S, Khrouf S, Boujelben Y et al: Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia. Mycoses 2011, 54(5):e499-e505.
13. Pfaller MA, Jones RN, Castanheira M: Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 2014, 57(10):602-611.
14. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A: Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of clinical microbiology 2008, 46(2):515-521.
15. Guzel AB, Aydin M, Meral M, Kalkanci A, Ilkit M: Clinical characteristics of Turkish women with Candida krusei vaginitis and antifungal susceptibility of the C. krusei isolates. Infect Dis Obstet Gynecol 2013, 2013:698736.
16. Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME: Boric Acid for Recurrent Vulvovaginal Candidiasis: The Clinical Evidence. Journal of Women's Health 2011, 20(8):1245-1255.
17. Vroumsia T, Djaouda M, Gaké B, Ebang Menye D, Akoachere Christie E, Tambe E, Vughosu Akindoh V, Njiné T: Prevalence of Vulvovaginal Candidiasis amongst pregnant women in Maroua (Cameroon) and the sensitivity of Candida albicans to extracts of six locally used antifungal plants; 2013.
18. Falagas ME, Betsi GI, Athanasiou S: Probiotics for prevention of recurrent vulvovaginal candidiasis: a review. The Journal of antimicrobial chemotherapy 2006, 58(2):266-272.
19. Nelson M WW, Margaret MW.: Prevalence of Vaginal Candidiasis and Determination of the Occurrence of Candida Species in Pregnant Women Attending the Antenatal Clinic of Thika District Hospital, Kenya. Open J Med Microbiol 2013:264–272.
20. Yesudhason BL, Mohanram K: Candida tropicalis as a Predominant Isolate from Clinical Specimens and its Antifungal Susceptibility Pattern in a Tertiary Care Hospital in Southern India. Journal of clinical and diagnostic research : JCDR 2015, 9(7):DC14-DC16.
21. Mukasa KJ, Herbert I, Daniel A, Sserunkuma KL, Joel B, Frederick B: Antifungal Susceptibility Patterns of Vulvovaginal Candida species among Women Attending Antenatal Clinic at Mbarara Regional Referral Hospital, South Western Uganda. British microbiology research journal 2015, 5(4):322-331.
22. Devi L, Maheshwari M: Speciation of Candida species isolated from clinical specimens by using Chrom agar and conventional methods, vol. 4; 2018.
23. Hu Z, Zhou W, Mu L, Kuang L, Su M, Jiang Y: Identification of cytolytic vaginosis versus vulvovaginal candidiasis. Journal of lower genital tract disease 2015, 19(2):152-155.
24. Vijaya D, Dhanalakshmi TA, Kulkarni S: Changing trends of vulvovaginal candidiasis. J Lab Physicians 2014, 6(1):28-30.
25. Morris AJ, Rogers K, McKinney WP, Roberts SA, Freeman JT: Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species. J Glob Antimicrob Resist 2018, 14:72-77.
26. Khan M, Ahmed J, Gul A, Ikram A, Lalani FK: Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. Infect Drug Resist 2018, 11:447-456.
27. Tumbarello M, Sanguinetti M, Trecarichi EM, La Sorda M, Rossi M, de Carolis E, de Gaetano Donati K, Fadda G, Cauda R, Posteraro B: Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. The Journal of antimicrobial chemotherapy 2008, 62(6):1379-1385.
28. Kullberg BJ, Arendrup MC: Invasive Candidiasis. The New England journal of medicine 2015, 373(15):1445-1456.
29. Arendrup MC, Patterson TF: Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment. The Journal of Infectious Diseases 2017, 216(suppl_3):S445-S451.
30. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ et al: Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016, 62(4):409-417.
31. Lewis JS, 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH: Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrobial agents and chemotherapy 2013, 57(9):4559-4561.
32. Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA: Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013, 56(12):1724-1732.
33. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD: Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Frontiers in microbiology 2016, 7:2173.